What did @itsmaywest actually say?
Not much, technically. The transcript is almost entirely a looping lyric or audio clip, repeating "I took the drugs and the drugs are working" over and over. The caption does the heavier lifting, calling semaglutide a "magic shot" that "literally changed my life." So what we're really fact-checking here is the implied claim underneath that celebratory framing: that GLP-1 receptor agonists like semaglutide work reliably and dramatically for weight loss, and that personal transformation stories are representative of what most people should expect.
To be fair, @itsmaywest doesn't make any specific medical claims. There's no dosing advice, no disease cure claim, no comparison between compounded and brand-name versions. It's a vibe post, not a health lecture. That matters for how we evaluate it.
Does the science back this up?
For a lot of people, yes, semaglutide genuinely does work, and the evidence behind it is stronger than most weight-loss interventions in recent memory. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that adults taking 2.4mg weekly semaglutide lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group. That's not placebo-level noise. That's a real signal.
The SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) went further, showing a 20% reduction in major cardiovascular events among people with obesity and existing cardiovascular disease. So the drug isn't just a scale number changer. There are serious downstream health benefits accumulating in the data.
The "magic" framing, though, deserves some pushback. Roughly 14% of participants in STEP 1 lost less than 5% of body weight. Response varies. And weight tends to return after stopping the drug (Wilding et al., 2022, Diabetes, Obesity and Metabolism). It works while you're on it, for most people. That's different from magic.
What did they get wrong (or right)?
They got the sentiment broadly right. Semaglutide produces meaningful weight loss in the majority of people who take it at therapeutic doses, and personal testimonials in this space are often consistent with what clinical trials show at the population level. Calling it life-changing isn't hyperbole for everyone.
What's missing, and this is where the 268,000 views become a concern, is any acknowledgment of who the drug is and isn't for. GLP-1 agonists are approved for adults with a BMI of 30 or above, or 27 with at least one weight-related condition. They are not approved as general wellness tools or aesthetic shortcuts. Side effects, including nausea, vomiting, gastroparesis, and in rare cases pancreatitis, are real and underreported in glow-up content.
The "magic shot" framing also erases the lifestyle component. The STEP trials all included dietary counseling and physical activity guidance. The drug was studied as part of a broader behavioral intervention, not in isolation. Presenting it as a standalone miracle flattens that context in a way that could mislead viewers.
What should you actually know?
Semaglutide is one of the most studied weight-loss interventions in modern medicine. The evidence is legitimate. But it's a prescription medication with real side effects, a specific approved population, and outcomes that vary from person to person. "The drugs are working" for @itsmaywest doesn't tell you whether they'll work for you, at what cost, or whether you're a candidate at all.
If you're curious about GLP-1 medications, the right move is a clinical evaluation, not a TikTok. A licensed provider can assess your BMI, metabolic health, cardiovascular risk, and history of pancreatitis or thyroid conditions, all of which affect whether semaglutide is appropriate. Compounded versions of semaglutide are not equivalent to FDA-approved Wegovy or Ozempic and carry their own risk profile that deserves separate scrutiny.
- Response rates vary: about 86% of STEP 1 participants lost 5% or more body weight, but a meaningful minority did not respond as strongly.
- Weight regain is common after discontinuation. This is not a short-term fix for most people.
- Side effects are underrepresented in patient testimonials. Nausea affects up to 44% of users in clinical trials.